In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
Colon cancer: RAS, BRAF, and HER2
Gastric cancer: PD-L1, HER2, and more
Pancreatic cancer: BRCA
Biliary cancers: FGFR and IDH1
Liquid biopsies
When to test

Presenter:

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.

Link to full program:
https://bit.ly/3j4hV8J

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Essential Biomarker Testing in GI Cancers